Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …

Insulin resistance and hepatic lipid accumulation constitute the metabolic underpinning of
nonalcoholic steatohepatitis (NASH). We tested the hypothesis that saroglitazar, a PPAR α/γ …

Background and Aims NAFLD is characterized by insulin resistance and dysregulated lipid
and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor‐α/γ …

Introduction: Novel peroxisome proliferator-activated receptor (PPAR) modulators (selective
PPAR modulators [SPPARMs]) and dual PPAR agonists may have an important role in the …

Background & Aims Cardiovascular disease is the leading cause of mortality in nonalcoholic
fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of saroglitazar …

Saroglitazar, a dual peroxisome proliferator activated receptor α/γ agonist, approved for
diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver …

Background & Aims: Saroglitazar, a novel peroxisome proliferator-activated receptor (PPAR)
α/γ agonist, was evaluated in preclinical and clinical studies to evaluate its effectiveness in …

Nonalcoholic fatty liver disease (NAFLD) encompasses a range of liver pathology ranging
from simple steatosis to varying degrees of inflammation, hepatocyte injury and fibrosis …

Non-alcoholic fatty liver disease (NAFLD) has become one of the most common causes of
liver diseases globally, with a projected exponential rise. In contrast to the exponential rise …

Abstract Background and Aim Saroglitazar, a dual PPAR α/γ agonist, is useful in
management of NAFLD and diabetic dyslipidemia. Here, we report the safety and efficacy of …